Article
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.
Haematologica - 1 Apr 2011
Soverini Simona, Vitale Antonella, Poerio Angela, Gnani Alessandra, Colarossi Sabrina, Iacobucci Ilaria, Cimino Giuseppe, Elia Loredana, Lonetti Annalisa, Vignetti Marco, Paolini Stefania, Meloni Giovanna, di Maio Valeria, Papayannidis Cristina, Amabile Marilina, Guarini Anna, Baccarani Michele, Martinelli Giovanni, Foà Robin
Abstract excerpt
BACKGROUND: In patients with Philadelphia-positive acute lymphoblastic leukemia, resistance to treatment with tyrosine kinase inhibitors is frequent and most often associated with the development of point mutations in the BCR-ABL kinase domain. We aimed to assess: (i) in how many patients BCR-ABL kinase domain mutations are already detectable at relatively low levels at the time of diagnosis, and (ii) whether...
Topics
- Adult
- Aged
- Amino Acid Substitution
- Female
- Fusion Proteins, bcr-abl
- Gene Order
- Humans
- Male
- Middle Aged